Merck & Co., Inc. is 176.9x more valuable than Zymeworks Inc. by market capitalization ($298.26 B vs $1.69 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ZYME | MRK |
|---|---|---|
| Market cap | $1.69 B | $298.26 B |
| US-listed rank | #2236 | #45 |
| Revenue (latest FY) | $105.97M | $65.01B |
| Net income (latest FY) | -$81.13M | $18.25B |
| Net margin | -76.6% | 28.1% |
| P/E (trailing FY) | - | 16.3 |
| SEC filings | 324 | 996 |
Merck & Co., Inc. is 176.9x more valuable than Zymeworks Inc. by market capitalization ($298.26 B vs $1.69 B).
In their latest fiscal years, Zymeworks Inc. reported $105.97M in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: Zymeworks Inc. and Merck & Co., Inc., or browse the full rankings.